ArticleEClinicalMedicine2026
Applying the 2024-revised McDonald criteria for multiple sclerosis using conventional diagnostic tools: a single-centre prospective cohort study in Germany.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 2024-revised McDonald criteria may enable earlier diagnosis of multiple sclerosis (MS) through inclusion of optic nerve involvement as fifth neuroanatomical topography, novel MRI biomarkers, cerebrospinal fluid (CSF) kappa free light chains (KFLC), and classification of radiologically isolated syndrome (RIS) as MS. Their applicability in routine practice remained for evaluation. Methods: In this prospective single-centre cohort study in Germany, adults presenting between October 1, 2020, and June 30, 2025, with a first demyelinating event or RIS were screened. Participants underwent conventional diagnostic work-up according to the 2017-revised McDonald criteria, including contrast-enhanced MRI, visual evoked potentials (VEP), and CSF analysis. Novel MRI markers and optical coherence tomography were not systematically available. Primary outcome was the proportion of individuals fulfilling the 2024-revised versus the 2017-revised McDonald criteria at baseline assessment. Findings: Applying the 2024-revised criteria, 201/215 individuals (93.5%) fulfilled diagnostic criteria for MS versus 181/215 (84%) using the 2017 revision (p < 0.0001). Additional diagnoses resulted from optic nerve involvement (55%) and RIS reclassification (35%). VEP identified optic nerve lesions in 89% of cases. Overall, 102/201 (51%) individuals fulfilled diagnostic criteria based on MRI findings alone, whereas 99/201 (49%) additionally required inflammatory CSF findings and dissemination in time. Interpretation: Application of selected components of the 2024-revised McDonald criteria increased the proportion of individuals fulfilling the diagnostic criteria, mainly through inclusion of optic nerve involvement and recognition of RIS. CSF analysis remained important for diagnosis and differential diagnostics. Further studies should evaluate the contribution of novel imaging biomarkers. Funding: No external funding was received.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.